The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/... Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.

Our CIMT coverage is out! 👉 Go to bit.ly/3SUQCOX to read a summary of select talks. #CIMT2025 Featured are: @ki.se‬  ‪@unileiden.bsky.social‬  ‪@ethz.ch‬  @niaidnews.bsky.social‬  ‪@dkfz.bsky.social‬  @lukasbunse.bsky.social‬  @biontech.bsky.social‬

Herzlichen Glückwunsch: 🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social 🏆️ Dr. Lukas Bunse @lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6

Huge congrats @lukasbunse.bsky.social, so well deserved, fantastic achievement. @hlsalliance.bsky.social @cn-hd.bsky.social @neurooncologyhd.bsky.social @mctneuroscience.bsky.social @platten-lab.bsky.social

PTPRZ1 was upregulated in GBM samples and was associated with cell stemness (GSC score). [...] bit.ly/416M1wV   @lukasbunse.bsky.social

Congratulations to David for being a finalist for the YPIC #proteomics Fund! We are happy to support his application at the Immunopeptidomics Platform HI-TRON and hope the fund will make this breakthrough project possible in collab with David from @lukasbunse.bsky.social lab at @dkfz.bsky.social

Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen www.nature.com/articles/s41... @lukasbunse.bsky.social @naturecomms.bsky.social

1/2 Super excited to see this finally out @naturecomms.bsky.social ! We developed an off-the-shelf T cell receptor T cell therapy for patients with glioblastoma from a peptide vaccinated patient. Looking very much forward to its translation within DKTK supported by HI-TRON!

Great fun to write this perspective with @lukasbunse.bsky.social @platten-lab.bsky.social @dkfz-iic.bsky.social @dkfz.bsky.social on a highly interesting study by the Bardeesy Lab. This study provides additional mechanistic rationale to combine IDH inhibitors with T cell activating therapies.

Could not be any prouder. Stellar work, fantastic lecture - day to remember. Welcome to the faculty @lukasbunse.bsky.social.